Clinical-stage Biotech

PharmAbcine's PMC-403: Advancing ISCLS Treatment with Tie2-Activating Antibody

PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome

Staff Reporter November 23, 2023 0

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announces the publication of...

Dr. Benjamin Winograd - Chief Medical Officer at K36 Therapeutics

K36 Therapeutics Announces Appointment of Benjamin Winograd, MD, PhD, as Chief Medical Officer

Staff Reporter November 15, 2023 0

K36 Therapeutics, Inc. ("K36"), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor KTX-1001 for t(4;14) multiple myeloma,...

Chime Biologics and Hope Medicine Collaboration

Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia

Staff Reporter October 26, 2023 0

Chime Biologics, a leading CDMO that enables its partners' success in biologics, and Hope Medicine Inc. (HopeMed), a science-driven, patient-centric, clinical-stage...

Clinical-stage Biotech

PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome

K36 Therapeutics Announces Appointment of Benjamin Winograd, MD, PhD, as Chief Medical Officer

Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia

Sculpt Clinics Introduces New Laser Hair Removal Technology

HEAL Foundation Announces Healthcare CSR Summit & Awards in New Delhi

Apsara Ice Creams to launch Muskaan initiative on its 53rd anniversary

Milann Fertility Center Celebrates World Breastfeeding Week with ‘Milann’s Embrace’ Initiative

DCN Dx to Showcase New Technologies at NextGen Dx 2024

Interesting Stories For You